Soligenix

Soligenix Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Soligenix (SNGX) as of Oct 18, 2026 is 92.66 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 101.66 % — a change of -8.86% (lower).

Cash Conversion

92.66 %

YoY

-8.86%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Soligenix is 2025 92.66 % . Cash Conversion Rate (OCF/Net Income) of Soligenix was 2024 101.66 % . It decreases by -8.86% lower compared to the previous year.

The Soligenix Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
81.40 USD
Jan 1, 2019
80.27 USD
Jan 1, 2020
64.76 USD
Jan 1, 2021
93.54 USD
Jan 1, 2022
91.67 USD
Jan 1, 2023
140.12 USD
Jan 1, 2024
101.66 USD
Jan 1, 2025
92.66 USD
The Soligenix Cash Conversion history
YEARCash ConversionYoY
92.66 %-8.86%
101.66 %-27.45%
140.12 %+52.85%
91.67 %-1.99%
93.54 %+44.44%
64.76 %-19.33%
80.27 %-1.39%
81.40 %-10.64%
91.10 %-40.67%
153.54 %+123.23%
68.78 %+87.02%
36.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Cash Conversion Rate (OCF/Net Income) of Soligenix is 92.66 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Soligenix changed from 101.66 % to 92.66 %, representing a -8.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Soligenix since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Soligenix with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Soligenix

All Key Metrics — Soligenix